Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Purchases 145,000 Shares

Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush purchased 145,000 shares of the stock in a transaction dated Monday, October 21st. The stock was purchased at an average price of $1.37 per share, with a total value of $198,650.00. Following the completion of the acquisition, the director now directly owns 145,000 shares in the company, valued at approximately $198,650. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Inhibikase Therapeutics Trading Up 15.2 %

IKT traded up $0.32 during trading on Wednesday, reaching $2.43. 470,766 shares of the company were exchanged, compared to its average volume of 183,455. The stock has a market cap of $17.53 million, a P/E ratio of -0.71 and a beta of 1.32. The firm has a 50 day moving average of $1.39 and a 200 day moving average of $1.51. Inhibikase Therapeutics, Inc. has a 52 week low of $0.80 and a 52 week high of $3.82.

Inhibikase Therapeutics (NYSE:IKT) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). As a group, analysts forecast that Inhibikase Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inhibikase Therapeutics stock. Armistice Capital LLC purchased a new position in Inhibikase Therapeutics, Inc. (NYSE:IKT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned approximately 8.17% of Inhibikase Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 3.81% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, October 14th.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.